dizziness
dizziness was captured in 4 source papers (996/8102). Interpret this as a source-backed named-event summary, not a head-to-head safety comparison.
ClinicalTrials.gov adverse events: Dizziness 365/1110 (32.9%) in Esketamine Nasal Spray (OP/MA Phase).
ClinicalTrials.gov adverse events: Vertigo 198/1110 (17.8%) in Esketamine Nasal Spray (OP/MA Phase).